Souhaitez-vous accéder aux communiqués récents ?

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Hepatorenal Syndrome Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...

Yaqrit progresses novel treatment into pilot study for primary sclerosing cholangitis and IBD. Results expected H2 2026

Yaqrit strengthens leadership team with leading biostatistician, an expert in liver trial design, and renowned US econ/finance strategist joining Board

Yaqrit announces eight upcoming presentations at the EASL Congress showcasing progress for drugs and devices in late stage trials in advanced liver disease

NIHR grant funds pivotal trial for Yaqrit's liver support device, DIALIVE, with potential to resolve life-threatening condition and impact survival.

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on...

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September...

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

New York, USA, March 25, 2024 (GLOBE NEWSWIRE) -- Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The rise in the number of people suffering from cirrhosis can be...

Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Human Liver Models - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Human Liver...